Citadel Advisors’s Biostar Pharmaceuticals, Inc. BSPM Stock Holding History

Citadel Advisors’s Portfolio BSPM Stock Details BSPM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-12,482	Closed	-$16K	–	8835
2017 Q3	$16K	Buy	+12,482	New	+$17.4K	﹤0.01%	7404
2016 Q1	–	Sell	-7,412	Closed	-$21K	–	9091
2015 Q4	$21K	Buy	+7,412	New	+$32K	﹤0.01%	7913
2015 Q2	–	Sell	-1,468	Closed	-$12K	–	9382
2015 Q1	$12K	Sell	1,468 -667	-31%	-$5.36K	﹤0.01%	8162
2014 Q4	$17K	Buy	+2,135	New	+$20.3K	﹤0.01%	7936
2014 Q3	–	Sell	-2,157	Closed	-$22K	–	8698
2014 Q2	$22K	Buy	+2,157	New	+$23.8K	﹤0.01%	7246
2013 Q4	–	Sell	-3,885	Closed	-$20K	–	7339
2013 Q3	$20K	Buy	+3,885	New	+$21.3K	﹤0.01%	6216

Other funds holding BSPM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BSPM Position: Q4 2017 in Review

Citadel Advisors sold out of Biostar Pharmaceuticals, Inc. (BSPM) in Q4 2017, closing a stake of 12,482 shares — an estimated $16K sold.

Citadel Advisors first reported a position in BSPM in Q3 2013 and held it in 6 quarters. The position peaked at $22K in Q2 2014. 5 funds tracked by Wall St. Rank hold BSPM as of Q4 2017.

Citadel Advisors reported no remaining Biostar Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Citadel Advisors sold 12,482 Biostar Pharmaceuticals, Inc. shares in Q4 2017, an estimated $16K.
Citadel Advisors first reported a position in Biostar Pharmaceuticals, Inc. in Q3 2013 and held it in 6 quarters.
Citadel Advisors's Biostar Pharmaceuticals, Inc. position peaked at $22K in Q2 2014.
5 funds tracked by Wall St. Rank held Biostar Pharmaceuticals, Inc. as of Q4 2017.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.